Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2020 Financial Results and Operational Updates. This conference call is being recorded today, February 25, 2021. I would like to turn the conference call over to Alina Doubrovna, Associate Manager of Investor Relations at Amarin.

Thank you, operator, and thank you to everyone for joining our fourth quarter and full year 2020 results. Before we begin, let me turn to our forward-looking statements. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of VASCEPA prescriptions; VASCEPA product and licensing revenues, cost, gross margin and other commercial metrics; our current plans and expectations regarding spending, including expenditures for the promotion of VASCEPA and for purchases of additional supply of VASCEPA; our current expectations regarding the adequacy of our financial resources; our current plans and expectations for product revenue growth, sales force productivity and product promotion in light of COVID-19 and the potential for adding attention to cardiovascular risk reduction drugs, like VASCEPA, as a result of COVID-19; our current plans and expectations related to patent litigation and expectations related to the potential loss of generic versions of VASCEPA by generic companies and by ourselves; our current expectations on the substance and timing of VASCEPA regulatory reviews outside of the United States; our current plans and expectations regarding the timing, goal and success of international expansion, including expectations regarding our ability to launch VASCEPA in Europe and our expectations in China for clinical trial results and potential to bridge REDUCE-IT results in labeling and promotion of VASCEPA through our partner in China; our current plans and expectations regarding VASCEPA exclusivity outside of the United States, including Europe and China; our current plans for commercial expansion in the United States with the entry of current and potential future generic competition; and our current plans and expectations regarding clinical studies of VASCEPA related to COVID-19. These statements are based on information available to us today, February 25, 2020. We may not actually achieve our goals, carry out our plans or intentions, or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially. So you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements we may enter into, amend or terminate. For additional information concerning the factors that could cause actual results to differ materially, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2020, which has been filed with the SEC and is available through the Investor Relations section of our website. We encourage everyone to read this document. This call is intended for investors in Amarin and is not intended to promote the use of VASCEPA outside its approved indication. An archive of this call will be posted on Amarin's website within the Investor Relations section. Making prepared remarks on today's call will be John Thero, President and Chief Executive Officer; and Michael Kalb, Chief Financial Officer. After prepared remarks, we will open the call to your questions. I remind you that multiple audiences typically listen to calls of this nature, including existing investors, potential new investors, employees, current and potential collaborators, and current and potential competitors. As always, in this call, we will attempt to provide constructive information without compromising our competitive and strategic positioning. I now turn the call over to John Thero, President and Chief Executive Officer of Amarin.

Hello and thank you all for joining us this morning. Because we provided substantial comments last month on our expected 2020 results, and our annual report has filed today reflects confirmation and formalization of what has already been reported, we intend today to be relatively brief in our prepared comments. 2020 was a year of considerable progress for Amarin with important achievements across multiple areas, including the launch in the United States of VASCEPA for the treatment of high-risk patients with persistent cardiovascular risk or PCVR, creating the foundation of our European commercial organization, progress by our international partners and important scientific advancement including demonstration of plaque regression through the administration of VASCEPA in patients evaluated in the EVAPORATE study. That said, 2020 was also a year we all faced great challenges with the COVID-19 global pandemic. Amarin specifically faced both the difficulties posed by the pandemic and the loss of our patent litigation in the United States for VASCEPA's original triglyceride-lowering indication. I am proud to say that the Amarin team rose above these obstacles with great determination and advanced the company across all areas of the business, including commercial, clinical and corporate. Let me begin with our most visible achievement in 2020, our record level of revenue. We reported annual net total revenue of $614.1 million in 2020, an increase of 43% compared to 2019. Both our full year revenue and our fourth quarter 2020 net revenue, which was $167.3 million are record levels for Amarin. Our revenue growth was led by increased prescription levels of VASCEPA in the United States. As you know, we launched the new PCVR indication for VASCEPA in January 2020. And in March 2020, consistent with most companies throughout the industry, we had to pull our sales team from the field due to the COVID-19 pandemic. Still, our team was able to pivot to digital platforms and other forms of outreach in education. Currently, our field team in the United States is making face-to-face calls with accessible target healthcare professionals where allowed. Change remains fluid due to COVID-19, particularly in various geographies. Our commercial teams remain committed and continue to adjust as needed in this unprecedented environment. Nonetheless, while VASCEPA growth in 2020 was slower than initially expected due to COVID-19, VASCEPA growth in 2020 compares well with the growth of peer drugs and in fact outpaced most other drugs indicated for cardiovascular disease treatment. In addition, we continue to make great headway with payers throughout 2020, which progress has continued into 2021. We have not yet solved the challenge of helping healthcare professionals diagnose and treat at-risk patients when patients avoid doctor visits and when patients avoid blood tests due to COVID-19 concerns. We envision the opportunity for further growth as the impact of COVID-19 recedes and patients begin returning to their healthcare professionals for preventative care. There are millions of at-risk patients whose cardiovascular risk is untreated, who are candidates for the cardioprotective benefits of VASCEPA. We recognize that it was only 13 months ago that we launched VASCEPA for the PCVR indication. We have much work remaining to effectively educate healthcare professionals and at-risk patients regarding this new treatment option. This large market needs and limited market awareness of VASCEPA, combined with VASCEPA's already substantial growth are three reasons we are confident in our ability to grow branded VASCEPA in the United States. We are aware of generic competition. We take all competition seriously. Nonetheless, we think that it would be a disservice to patient care in the United States and irresponsible to our employees and investors if we cease branded product promotion in the face of generic competition in this atypical generic market. Without further market education, use of VASCEPA will be unnecessarily limited and patient care will suffer. If, for example, VASCEPA was a household name that had been promoted for a decade, or if VASCEPA was a high-priced product, our decision to continue promotion might be different. We believe that the upside potential from continued market expansion in the United States remains considerable. From the start, we have priced VASCEPA to be affordable. Even price watchdog groups have commented that the pricing of VASCEPA is cost-effective. We could make money through the launch of an authorized generic product in the United States. But doing so would not maximize the revenue and profit potential of the product and would result in many healthcare professionals and at-risk patients never learning about this important drug and its still very recent PCVR indication. In addition to VASCEPA being an atypical market for generics, because of VASCEPA's affordable pricing, and because it is not a mature market. As expressed previously, based upon industry data, the skinny label for the launch of the generic product covers no more than approximately 7% of VASCEPA's prescriptions, or approximately $40 million in revenues per year based upon 2020 U.S. net product revenue. We have patents covering VASCEPA promotion for cardiovascular risk reduction. Cardiovascular reduction is not in the label of the available generic product and was not contested in past litigation. Disappointingly, from a societal health perspective, to our knowledge unlike Amarin generic companies are not investing in market education or other initiatives to expand VASCEPA usage to help more at-risk patients, and they are not investing in clinical study of VASCEPA for all their potential uses. Also, to our knowledge, generic companies and their suppliers have not made the investment in capacity expansion which Amarin has made. Currently, there is only one launched generic in the market and there have been reports of periodic stock outages for that product creating week-to-week fluctuations in the level of prescriptions filled by retail pharmacies with the generic product. These fluctuations in the generic product availability impact the level of prescriptions filled with branded VASCEPA. While capacity for generic competition may increase over time, based upon information available to us currently, we anticipate that capacity via their current suppliers will remain a fraction of the capacity of Amarin suppliers. Various insurance companies and patients have expressed to us that they have found the generic product to be more expensive than the branded product on a net price basis after factoring in applicable discounts. Drug pricing can be tricky. The generic product can claim that its wholesale acquisition price is 12% below the price of the branded product. However, that reference is misleading, as it is before rebates, discounts, and co-pay cards, the impact of which makes the net price of the branded product less expensive. Clearly, various payers have not found the pricing of the generic product to be sufficiently compelling as managed care coverage for branded VASCEPA has continued to improve overall since the generic product was launched in November 2020. Separate from these market dynamics, Amarin filed a cardiovascular risk reduction patent infringement lawsuit against Hikma and a healthcare insurance company based upon various facts, including Hikma's promotion of its product in a manner targeted at cardiovascular risk reduction uses, and the health insurer's coverage of the generic product for cardiovascular risk reduction, each of which we believe are part of a collection of activities that infringe our cardiovascular risk reduction patents. We today have no update to provide regarding that litigation. We refer people to the court filings for more details. Overall, we remain confident that there is a large market need for VASCEPA, and we believe we can grow this market faster than generics can take share. The first quarter of each year is historically a challenge for VASCEPA due to seasonal factors. In particular, in Q1 of each year some patients elect to not fill their prescriptions for branded prescription medicines such as VASCEPA due to beginning of the year deduction limits under their insurance plans. Such deduction limits go into effect at the beginning of each calendar year under many insurance plans. Due to this seasonality, we encourage investors to continue to review VASCEPA growth on a year-over-year basis. In addition to the prescription growth we expect to experience as we progress beyond the seasonal factors, we anticipate an acceleration in VASCEPA growth as the impact of COVID-19 recedes. In recent months, you've likely read multiple accounts of increased rates of heart attacks and other cardiovascular events. These increases have been attributed to patients not seeking preventative cardiovascular care due to COVID-19. You likely also witnessed a resurgence of COVID-19 in the fourth quarter of 2020. As a result of that resurgence, we pulled back on certain promotional initiatives, including television advertisement. As patients get vaccinated and begin to return to their doctor's offices for non-urgent care. We anticipate VASCEPA increasingly becoming part of the prescribed treatment regimen for at-risk patients. When the impact of COVID-19 recedes, it is our intention to restore various promotional initiatives. Currently, we are planning for this to begin occurring in the second quarter of 2021. Next, I will comment on the progress we're making towards approval and commercial launch in Europe. In late January, we were delighted to receive a positive CHMP opinion for icosapent ethyl under the brand name VAZKEPA for cardiovascular risk reduction. And we now expect a final approval decision from the European Commission in April. Over the past six months, we have been accelerating building commercial infrastructure to support commercial launch in Europe. And we now have a dynamic team of more than 50 experienced professionals in place, which we expect to grow to approximately 200 people by year-end 2021. The people we have hired thus far are very impressive, and we are making important progress in preparing for VAZKEPA's commercial launch in Europe. As previously reported, we are planning for a staged launch on a country-by-country basis in Europe based upon reimbursement availability likely starting in Germany. We continue to engage in pre-label market access dialogues where permitted. We are preparing for more formal discussions with national agencies regarding product pricing once VAZKEPA receives approval from the European Commission. Further discussion of our approach to market access in Europe is outlined in one of our FAQs in the Investor Relations section of our website. While market access negotiations will vary from country to country, we believe that we are well-positioned to achieve reasonable pricing based upon the high rate of cardiovascular events in Europe. The lack of approved therapy for the indication for which VAZKEPA is positioned to address the demonstrated efficacy and safety profile of this unique drug and the history of reimbursement for this important drug, particularly in Canada, which is also a government-run healthcare system, and in the United States, of course. The approval and launch of VAZKEPA in Europe represents an exciting opportunity for Amarin to make a difference in the lives of millions of patients who are at risk for cardiovascular events. Regarding the opportunity for VASCEPA in China, our partner Edding has made considerable progress. Last November, we shared positive data from Edding's Phase 3 clinical study of VASCEPA in China. In January, we were delighted to share that icosapent ethyl was added to the Chinese Society of Cardiology's treatment guidelines, increasing to 13 the number of medical societies that have included icosapent ethyl in their medical treatment guidelines or otherwise recommended use of this important drug for cardiovascular risk reduction in at-risk patients. Earlier this month, regulatory authorities in China, the Chinese NMPA accepted Edding's new drug application for review of VASCEPA, which is another milestone on the path to approval for Edding. Edding currently anticipates receiving approval of VASCEPA in Mainland China near the end of 2021 and also anticipates approval of VASCEPA in Hong Kong near the end of 2021. With approximately 180.4 million hypertriglyceridemia patients in China in 2019, and a history of rapid adoption of statin therapy in China, there is a significant medical need and a meaningful market opportunity for Amarin and Edding. Regarding the rest of the world, our commercial partners in Canada and the Middle East continue to make progress, and Amarin is eyeing other potential international opportunities for VASCEPA after we progress this important product through approval in market access in Europe. We do not want commercialization in these smaller markets to distract us from what needs to be accomplished in Europe. With that update and review, let me turn the call over to Mike Kalb, our CFO for a more detailed discussion of our financials. Mike?

Thanks, John. We encourage investors to review our 2020 annual report on Form 10-K, now our corresponding press release as issued this morning. Both of these can be found on our website. They contain discussion of our fourth quarter and full year financial results including various details which go beyond the highlights I will cover in today's call. John noted our record levels of net revenue in both the full year and the fourth quarter of 2020. These increases were driven primarily by increased volume of VASCEPA sales to customers in the United States. The net price in VASCEPA, while it increased modestly in 2020 has essentially remained flat for many years. It is not possible to quantify the impact of COVID-19 on our 2020 net revenue, although we are certain that such impact was significant. Additionally, while it is also not possible to quantify the impact of the generic product launched in November 2020 on our net revenue, we do not believe such had a material impact. We do not breakout operating results by geography. However, the contribution to our business from commercial operations in the United States has been improving, while we have commenced making increased investment in Europe. As mentioned earlier this year, Amarin anticipates 2021 operating expenses of approximately $550 million to $600 million, which represents an increase of approximately 10% to 20%, compared with 2020 levels. Included in these anticipated expenses are increased costs associated with Amarin's commercial launch preparations, and initial launch in Europe, as well as continued U.S. promotional activities. Also included in these anticipated expenses is an assumed sales force in the U.S. of approximately 750 to 800 professionals consisting primarily of sales representatives and their managers. Due to the uncertainties regarding COVID-19 and potential generic supply, Amarin will continue to withhold 2021 revenue guidance for VASCEPA in the U.S., until there is greater clarity on the impact of these issues. As of December 31, 2020, Amarin reported aggregate cash and investments of $563.4 million, consisting of cash and cash equivalents of $187 million, and liquid short-term and long-term investments of $314 million and $62.5 million respectively. Furthermore, during the fourth quarter of 2020, we made our final royalty-like debt payment, which previously was 10% of net product revenue since VASCEPA was launched. We now have no debt. We reiterate that based on our current plans, we believe that our existing resources are sufficient to fund VAZKEPA's launch in Europe and to get us to cash flow positive on a consolidated basis. With that financial overview, I will now turn the call back to John for closing remarks.

Thanks, Mike. Like all of you, we entered 2021 with great hope that the vaccines developed by our industry colleagues will stem the tide of the global COVID-19 pandemic, yet aware that there will continue to be a need for effective therapeutics as well. Towards that end, we maintain our support of multiple investigator sponsored studies of icosapent ethyl to treat and prevent COVID-19. The first of these studies demonstrated encouraging results. After we see further study results, we will assess the potential role of VASCEPA related to COVID-19 and other infectious diseases where inflammation is an issue. Amarin has a very dynamic year ahead. 2021 is a year of execution for Amarin. And we are working hard to attain our goals including: meaningful growth of branded VASCEPA revenue and contribution in the United States, the successful approval and launch of VAZKEPA in Europe, the successful approval of VASCEPA in China, and continued scientific advancement, leading to potential new market opportunities. I'd like to take this opportunity to express my gratitude to the Amarin team, including our employees, our commercial partners, suppliers, and the scientists and physicians supporting VASCEPA's scientific, regulatory, and/or commercial advancement. And I thank our shareholders for your continued support and encouragement as we advance this new paradigm in cardiovascular risk management. With that, operator, we are now ready to open the call to questions.

Thank you. The first question is coming from Louise Chen. Louise, your line is live. Please announce your affiliation and pose your question.

Hi, Louise Chen with Cantor. Thanks for taking my questions here. So I had a few questions. First question I had was how should we think about this first quarter 2021 sales for VASCEPA, given the pandemic headwinds that we have this year when compared to last year? And then, second question I had was what gives you confidence that you can continue to grow faster than the market for generics, even if more generics can enter the market later this year? And then, last question I have is, how do you think about the peak end-market sales in China and what that means to you in revenue? Thank you.

Louise, good morning. It's John. Thanks for the questions. With respect to Q1 sales, we're in the middle of the quarter and can't comment too much on the middle of the quarter activities. But as we commented during the prepared remarks, there are a couple of headwinds that we face in the first quarter. One, of course, is COVID. And that's been volatile. Certainly, there is some good news in the media recently about event rates going down. We've seen periods in the past, like we saw in sort of the September/October timeframe, whereas COVID pulled back the prescriptions in the United States of VASCEPA went up. I think it's early to be predicting that, but whether that's immediate or whether that's more of a Q2 phenomenon, we are hopeful and have confidence that that's going to happen. Two is the impact of the generic supply, which appears to be relatively fixed here, varying week to week, but it is taking a slice that I think you'd see the numbers. It's quantified. It bounces up and down. And then, of course, there are those headwinds that we get seasonally every Q1, and particularly, in the January and February timeframe has impact. And for those who aren't familiar with that, you can think about a drug like VASCEPA, which somebody has insurance and co-pay card, they can get for $9 for a 30-day supply. But that co-pay card doesn't pick up every dollar from dollar one if somebody doesn't have insurance. So if a patient has a $3,000 deductible on their insurance, and these patients tend to be on multiple therapies that they are used to paying $9 here and $25 there and $30 there, and then maybe a monthly bill of $100 for their portfolio of therapies. And they've got a $3,000 deductible, they go in, in January to get their prescriptions filled, instead of being an aggregate tab for the 5 of them for $100, they come back for the charge and, say, $3,000, those patients end up billing their pain meds, but they need - many of them just can't afford to fill all their medications. So they don't fill something as important as preventative cardiovascular care. Then historically, we've seen a sort of rebound in those scripts in March, and then particularly in April and May. So we're counting on that type of thing happening here again in the first quarter. The promotion that we have been doing, because of COVID, we did pull back a bit during the fourth quarter and have continued to be somewhat constrained here in the first quarter relative to promotion. You've seen as much television advertisement, for example. We're preserving those resources with a view that as COVID pulls back further, we will ramp that up. So we're currently anticipating year-over-year growth in the first quarter versus last year, but we're not providing any quantified guidance on it at this point in time. With respect to why we believe that we can grow faster than generics, that's a complex topic. And I would begin with the fact that this really is very much an atypical generic market. Atypical in the sense that, for the generic that's launched, greater than 93% of the use is off-label. As I discussed, VASCEPA is not a mature market. Most people don't know about it. Yet, this is a multibillion-dollar opportunity that we think we're focusing on. We've just launched and just 13 months ago we just began the launch. We're focusing on patient education. And this is not an expensive product, so it's not like the generics coming in, they'd be rushing after the generic, because it's less expensive. To the contrary, we've seen managed care coverage continue to expand. And then, the manufacturer of this product requires significant investment that Amarin has made and supported over multiple years to create efficiencies. But lead times here for product supply is long and then expensive. So probably contributes to why only one of the three approved generics have launched at this point in time. And the one that has launched has commented that their gross margins on that product are lower than what it is for other products, because of the relatively high cost for the production of this high-quality complex product to manufacture. I remind you that Epadel, which is a nuclear-based product in Japan has been generic for over a decade and is still greater than 60% branded. So we think it is the right thing for patient care for us to continue to focus in on increased promotion in the United States. I know our sales team in the field is confident that we can grow. What we need to do is have patients go back to their doctors. And I think if patients were regularly going to the doctors for ordinary care, we will be growing at a rate that it would be convincing to many people that we should be in a world faster than generic. This is just a big, big market. And, of course, and a topic in generic is U.S. only. And in Europe, for example, is 10 years that we're respecting regulatory exclusivity, and then patents that could take us out potentially as long as 2039. What was your third question? Peak sales in China, right, right, right. So I think there we need to recognize it's a very large market in China. Unfortunately, cardiovascular disease is a global phenomenon. We're working with a very good partner, Eddingpharm. They've got a lot of experience in taking products through the reimbursement process, which in China will be important as it is in Europe. And we put together a very good team in Europe to handle this. We first need to get the product approved in China and see what the label ends up being. And I don't want to step on the toes of Edding; they're responsible for the pricing there. We've got some say in it, but let's get these labels first and then they will go province by province, aim towards the approval, but the rate of uptake of statin use has been high in China. And, certainly the cardiovascular need is high in China. I would remind folks that the terms of our agreement with Edding are that there are various milestone-based payments, but also, we will be manufacturing the product for them and doing that on a cost-plus basis. And then there are tiered royalties on top of that that are starting in double digits and sort of escalating up through that. So it's a big, big potential opportunity for us. So let's get it approved first, see what the label is. And then, go through the provinces for reimbursement before we get in too much quantification there. So - and then, again, I don't want to step on Edding's toes. They're a perfect partner. Hopefully, those comments are helpful.

Yeah, thank you.

Thank you. And the next question is coming from Ken Cacciatore. Ken, your line is live. Please announce your affiliation and pose your question.

Hi, it's Ken with Cowen. Thanks, John, for all the details. I appreciate them. Just wondering if you could give us a sense of what would be the best analog that you would like to point us to in Europe, in terms of pricing? Any recent cardiovascular product that you think would be best comparison, maybe a sense of where the kind of average branded statin pricing was? And any nuance around that would be wonderful. And then, just thinking about the U.S. spending as you embark on the European opportunity, sounds like you're going to try to nuance a little bit, obviously, be as aggressive as you can in the U.S., but be thoughtful about how that balances against the investment in Europe. Just wanting a little bit more detail on how you're going to try to strike that relative balance. Thanks so much.

Hey, Ken. Good morning. Thanks for the questions and giving free advertisement. We're looking forward to being at your conference next week, where I'm sure you'll have many other questions for me. With regard to an analog in Europe, I think one of the things that I would emphasize and I think that's the positive is that really there is no good analog. And, the way that reimbursement works for market access perspective, being a unique product from that perspective is probably a good thing. So I think what we can point to is that from a pharmacoeconomic perspective, the cost of things like heart attacks and strokes are very expensive. And not only at the time of occurrence, but something like a stroke could go on for years. So, those kinds of pharmacoeconomic arguments have been effective in the United States; they were also effective in Canada. Canada is also, of course, a single payer government healthcare system, and we and our partner there were pleased that reimbursement came along faster than what we expected. And I think following the pharmacoeconomic arguments to provide a reasonable price number. So as we go into Europe, there really is no direct analog, but there is a very substantial market of patients with persistent cardiovascular risk for which there is no therapy today, a product in VAZKEPA, that has proven outcomes data, usually products aren't launching with outcomes data, which also sort of takes away an analog for other products, and it’s first market, and it already has recommendations from the two leading medical societies, the European Society of Cardiology and the European Atherosclerosis Society. So we're looking forward to a launch in Europe that's considerably different than the launch we had in the United States, when we launched in the United States, it was a step launch based off of initial biomarker change indication does lowering very high triglycerides, we didn't have outcomes data. There's lots of generic competition, and it was a niche market in Europe, we're going in with outcomes data, and no direct competition. And, I think, we should in Europe like we've done in the United States, focus on how can we get this reimbursed in a way that we can help as many people as we can in terms of at-risk patients in Europe. Market access, of course, is a country-by-country proposition in Europe, and we've talked about in the past that we'll be looking to prioritize that. With regard to spending, Amarin is increasingly becoming a multinational company. For years, we limited resources to start, but we're doing what we can in the United States commercially, as we focus it on investments in R&D particularly for the REDUCE-IT study. And then, after the positive results of the REDUCE-IT study in late 2018, we began building our U.S. commercial infrastructure and expanded that further in late 2019. Of course, we doubled and coming into 2020, started the launch and then got slowed down here by COVID. Throughout this past, really two years, the overall business on a cash flow basis has generally operated pretty close to cash flow neutrality, we've had some quarters that were slightly positive, and some quarters that were slightly negative. Our view is that there will be variables from quarter to quarter, that we should be growing revenues in the United States. And, the spending may be somewhat variable, but we're looking forward to both increased revenues and increased positive contribution coming from our U.S. activities. The European investment, we think is important; it's the eighth of that investment as sort of the irony of the - faster the countries get market access, the faster that we would potentially be spending in Europe, of course, then translates into revenues coming in faster as well. So, in Europe right now, we've got a core team. And, of course, our corporate team in Dublin, the core sort of marketing team set up in Switzerland. And then a field team that we've started to put together for Germany on a non-branded basis working on market awareness. Once we get approval, which we're anticipating in the April timeframe, we'll be able to ramp up that sort of pre-launch promotion. And then, assumedly launch in Germany and potentially other countries subject to market access. So we've talked about the size of the sales team in Europe, increasing during this calendar year to approximately 200 people that assumes a certain level of market access, if the market access is faster than that we would increase our spending faster than that. If we're promoting, and say, Germany, and that's against the speed and get revenues, that begins to pay for itself, and then that is less of a burden, as we're going into other countries that were getting market access faster in other countries, maybe we're launching a little more simultaneously, the amount of spend will differ based upon that. In any of those cases, we believe that our current capital resources are sufficient to make the investment necessary to be successful in Europe. But first, we need to get the regulatory approval then we need to get started on market access, we need to do some pre-launch education, and then we'll get out into launching each country. And as we do so we'll certainly have much more feedback relative to spending. The European market focus for us should be a bit more concentrated than it is in the United States probably not need there for television advertisement, much more, maybe a digital focus. And, there's a bit more concentration of at-risk patients with cardiologists in Europe, which we think will help as well. So I know I haven't provided much quantification there, but at least that some background information that may be useful to you.

Okay. Thanks. Looking forward to the conversation next week. Thanks so much.

Thanks, Ken.

Thank you. And the next question is coming from Michael Yee. Michael, your line is live. Please announce your affiliation and pose your question.

Hi, this is Dennis Sting on for Michael Yee at Jefferies. Congratulations on the progress. I just have two questions, one on the U.S. and one for Europe. So in the U.S., generics have launched for about a quarter now? How often do you guys encounter generics on the ground? And what are physician prescribing patterns in areas, where you having to compete with them? Or does this decision happen at the pharmacy? And how has that changed from Q4 to Q1? And then my second question on Europe. Have you been engaging in conversations with potential partners and has there been a lot of interest, in what's their biggest area of pushback? Thanks so much.

Thanks for the question. So, regarding generics in the United States, there's one launched generic at this point in time; it came out at the beginning of November. We're seeing it in various respects. We're seeing it from patients sometimes calling us to complain that the cost of that generic is higher than what they were paying for the branded product. We're seeing it from various managed care companies that have been interacting with us, recognizing that the generic is causing them more on a net basis. And that's driven in some cases to improve the managed care coverage. Most physicians are not highly aware of the generic that's out there. And, as you see through our litigation, we have seen activity that we think is inappropriate by the generic company and at least by certain payers that we think create situation where they're trying to go beyond, they approved label for that product. Right now, they are self-described as being limited by supply. There have been outages at various pharmacies, with some complaints by patients where the patients are going to get their script filled, the pharmacist looks for other uses of the generic here, tries to get it, can't get it, sends the patient away, I'll try to get it and then still can't get it, and that's frustrating to patients. So, there's learning going on, and we're always trying to make sure that all parties involved, whether it be payers, physicians, patients, pharmacists are aware of, there's skinny label of the generic, in fact that the pricing of the random product is often less than a net basis than the generic product, and the risk of outages relative to the branded product, all while trying to introduce this event to the market as the awareness of the product is still pretty low; just launched 13 months ago, and much of that launch has been during a pandemic. So we see there's significant educational need and opportunity out there. With regard to European partners, I guess I'll approach your question in two ways, but I'm not sure when you're referring to partners, whether you mean, sort of the - what we've gone through in the past, or what we might be going through in the future. In terms of going through in the past, we did before deciding to go for a self-launch in Europe review partnering opportunities with larger companies in Europe, and we found interest from that. But we also convinced ourselves that the enormity of the opportunity in Europe, justifies an investment on our own to create the required infrastructure in Europe, and that we know the product best. And, we have a lot of experience with the product in the United States and Canada, for example. On reimbursement in that approaching with ourselves provided greater upside value to our shareholders than partnering it off to some larger company. So we went through that previously, and described that process previously. So perhaps you're referring to the fact that we've talked about Europe as being sort of three levels of countries, right. So there's large countries, there's mid-sized countries, and then there's smaller countries. In smaller countries, it is true that it probably does not make as much sense for Amarin to create infrastructure there, where there are local companies that can do that potentially better than we can. We have been doing some planning and thinking in that area, but the biggest markets are the EU-5 starting with Germany, and most of our attention has been on getting ready for approval and preparing for market access reimbursement negotiations in the Big Five and in some of the sort of the medium size countries. So, we'll have more to say relative to partnering in the smaller countries after we get approval and get a little bit further, but first and foremost, we need to be successful in the larger country. So hopefully, those comments are helpful.

Yeah, thank you very much.

Thank you. And the next question is coming from Jessica Fye. Jessica, your line is live. Please announce your affiliation and pose your question.

Hey, there, good morning. It's Jess Fye from JPMorgan. I was curious what you think of some good price analogs for China?

Hi, good morning, Jess. I think, first, we see what the label is going to be in China. We are certainly pleased with the recommendation coming out of the medical society in China recommending the use of icosapent ethyl for addressing cardiovascular risk reduction. But let's see what China FDA has to do relative to the label first. And then, China is a complex market, the reimbursement can be really different from province to province. And then there's cash sales and reimbursed sales, it really is the domain for our partner adding in one of the reasons why we picked them, is that they're really good at this type of thing. So it's just I think early for us to be setting a price. And I don't want to step on the toes of Edding. This is their domain. This is why we selected them as a partner. So, it's a bit premature for us to provide an analog at this point.

Okay, thank you.

Thank you. And the next question is coming from Joel Beatty. Joel, your line is live. Please announce your affiliation and pose your question.

Hi, this is Joel Beatty from Citi. Congrats on the progress. First question is, are there any examples of analogs in Europe in terms of trajectory of the launch? And how to think about drugs launching into large market indications there? And then the second question is, for the U.S., could you characterize the current level of awareness of VASCEPA, and how changes in awareness can impact sales? Thanks.

Joel, good morning. Relative to analogs for Europe, that's one that we have studied and studied and studied. And really there - I can't, we have not found any product that has launched with outcomes that have no direct competition for a patient population of this size. There just isn't a good analog. We have seen products with lesser results do quite well in Europe, but I think we need to first get approval then get into the market - the market access side of things. And there, I think we're probably going to try to be thoughtful, not greedy, with the aim to try to help as many people as possible. But I think it's premature for us to really predict an analog at this point. So the - with regard to the United States and awareness, we've done some market survey work there. And, Aaron Berg, who runs that side of things is with us. And, Aaron, maybe you can cite some of our recent awareness survey and your sense of where the market is relative to - from an awareness perspective.

Sure. Overall, un-aimed awareness of VASCEPA is very low. We just launched the indication right before the pandemic. We had just expanded the sales force. We significantly expanded our target audience of HCPs, and then essentially shut down as most of the industry, so we never got that off the ground and - to have the ability to build that awareness. And, of course, without awareness, you're not going to get understanding and prescriptions. And that's where it starts. We started to see recovery through the summer. As we're getting toward physician and sales force back out there, and starting to build more. But then again - and then, as you headed into Q4, there was a significant resurgence and it dampened the promotional efforts as well. So our awareness overall from an HCP perspective is low and even more so with consumers. In fact, even though we ran the campaign, the awareness stayed in the teams through the second half of 2020. So we've got a lot of opportunities, still a very small brand. Overall, we hope as we head into the recovery here, as we're all optimistic about our promotional efforts, will take hold of patients will return to physicians, and the cycle will begin. And, yeah, we'll see that growth as a result of them, but it does start with awareness.

And just on the Europe piece, just one other comment. I remind people, because there's been some media articles recently that have maybe taken us out of context. We are not in Europe going after every single patient that has elevated triglycerides. Who we're going after are patients who despite cholesterol management, particularly statins, continue to have cardiovascular risks? So we're not trying to replace statins and it is a substantial market, but it's not the 80 million patient market as shown up recently in some media articles. And we do provide some market statistics in our 10-K filing today that are consistent with what we've talked about in the past. But I just wanted to - in light of some recent media pieces, emphasize that it's not every patient with elevated triglycerides that we're going after in Europe. So I appreciate the interest in questions. We've taken an hour here. I know everybody's got to get on to other things. So we're presenting tomorrow at the Leerink Conference, Cowen next week. I'm sure there'll be additional questions there. I thank you all for your support and interest, and look forward to providing updates here as we continue to progress. Thanks everybody. Have a great day.

Thank you, ladies and gentlemen. This does conclude today's conference call. You may disconnect your phone lines at this time. Have a wonderful day. Thank you for your participation.